Roche suffers Ocrevus knockback by NICE

05:12 EDT 6 Apr 2018 | Pharmafile

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, as it managed to bring in $902 million in sales during the 2017 financial year.

After receiving European approval at the beginning of this year, it would have been hoping to consolidate these sales and push the drug forward into being a solid blockbuster earner in the years to come.

read more

Original Article: Roche suffers Ocrevus knockback by NICE


More From BioPortfolio on "Roche suffers Ocrevus knockback by NICE"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...